Terminated PHASE1 INTERVENTIONAL 2-arm NCT01698567

Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

Antithrombin III Supplementation for Infants Undergoing Cardiac Surgery With Cardiopulmonary Bypass.

Sponsor: University of Rochester

Updated 6 times since 2017 Last updated: Mar 21, 2016 Started: Jul 31, 2012 Primary completion: Mar 31, 2016 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Challenges enrolling subjects in study

Other terminated trials from University of Rochester

See all terminations from University of Rochester

Other Congenital Heart Disease trials with similar outcome

Browse all Congenital Heart Disease trials

This PHASE1 trial investigates Congenital Heart Disease and is currently terminated or withdrawn. University of Rochester leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Rochester

Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States